Sign In
Buy THTX
$3.39
+0 (+0%)
At Close: Dec 24, 2025
Theratechnologies Inc. (THTX) CEO Paul Levesque on Q1 2022 Results - Earnings Call Transcript
02:55pm, Wednesday, 13'th Apr 2022
Theratechnologies Inc. (NASDAQ:THTX ) Q1 2022 Earnings Conference Call April 12, 2022 8:30 AM ET Company Participants Paul Levesque - President & CEO Philippe Dubuc - SVP & CFO Christian Marsolais - S
Theratechnologies to Announce Financial Results for Its First Quarter 2022
05:05pm, Thursday, 31'st Mar 2022
MONTREAL, March 31, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innova
MONTREAL, March 08, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or “the Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and
Theratechnologies Inc. (THTX) CEO Denis Boucher on FY2021 Results - Earnings Call Transcript
10:14am, Sunday, 27'th Feb 2022
Theratechnologies Inc. (THTX) CEO Denis Boucher on FY2021 Results - Earnings Call Transcript
Theratechnologies to Announce Financial Results for Its Fourth Quarter and Full Fiscal Year 2021
07:00am, Thursday, 10'th Feb 2022
MONTREAL, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innovat
Theratechnologies to Present at the Credit Suisse 30th Annual Healthcare Conference on November 11, 2021
07:30am, Wednesday, 03'rd Nov 2021
MONTREAL, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovat
Theratechnologies Inc. (THTX) CEO Paul Levesque on Q3 2021 Results - Earnings Call Transcript
11:24am, Wednesday, 13'th Oct 2021
Theratechnologies Inc. (THTX) CEO Paul Levesque on Q3 2021 Results - Earnings Call Transcript
Theratechnologies Q3 Earnings Lags Consensus As Trogarzo Sales Decline
09:00am, Wednesday, 13'th Oct 2021
Theratechnologies Inc (NASDAQ: THTX) reported Q3 sales of $17.85 million, +27% Y/Y propelled by higher Egrifta sales of $11.22 million, +64%. The revenue missed the consensus of $19.66 million.
Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2021 and Provides Business Update
07:00am, Wednesday, 13'th Oct 2021
- Q3 FY2021 consolidated sales grow 27% over Q3 FY2020 –
Theratechnologies to Present at the H.C. Wainwright 5th Annual Nash Investor Conference
08:30am, Wednesday, 06'th Oct 2021
MONTREAL, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innovat
Theratechnologies to Announce Financial Results for Its Third Quarter Fiscal 2021
08:30am, Wednesday, 29'th Sep 2021
MONTREAL, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (TSX: TH) (NASDAQ: THTX) (Theratechnologies), a biopharmaceutical company focused on the development and commercialization of innova
Theratechnologies' IV Push Form Of HIV Treatment At Par With IV Infusion
12:27pm, Wednesday, 22'nd Sep 2021
Theratechnologies Inc (NASDAQ: THTX) has announced results from a study evaluating an intravenous (IV) push form of Trogarzo (ibalizumab-uiyk) for HIV-1 infection. The TMB-302 study was conducted b
Theratechnologies Announces Positive Results for Trogarzo® IV Push Administration Study
08:08am, Wednesday, 22'nd Sep 2021
- TMB-302 study results demonstrate that there was no difference in pharmacokinetics between IV Push and IV Infusion -
Theratechnologies to Present at the Cantor Fitzgerald Global Healthcare Conference on September 29, 2021
09:02am, Thursday, 16'th Sep 2021
MONTREAL, Sept. 16, 2021 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (Theratechnologies) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercialization of innova
Theratechnologies Announces Publication of TH1902 Preclinical Data in Peer-Reviewed Journal, Cancer Science
09:08am, Friday, 13'th Aug 2021
MONTREAL, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Theratechnologies, Inc. (Theratechnologies, or Company) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company focused on the development and commercializati
